c-Jun N-terminal kinase and p38 mitogen-activated protein kinase (JNK and p38 MAPK)

c-Jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinases (MAPK) are essential components of the stress-activated protein kinase (SAPK) signaling pathways [PubMed: 22388264]. These kinases are activated in response to diverse stimuli, including environmental stress, inflammatory cytokines, and growth factors [UniProt: P45983, Q16539]. JNK is primarily known for its role in regulating apoptosis, cell growth, and insulin signaling through the phosphorylation of the c-Jun transcription factor [PubMed: 11526482]. In contrast, the p38 MAPK pathway is a central regulator of the biosynthesis of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta [PubMed: 10830115]. Both pathways are critically involved in the pathogenesis of chronic inflammatory conditions, such as rheumatoid arthritis and Crohn's disease, as well as neurodegenerative disorders and cancer [PubMed: 25610226]. Therapeutic strategies often involve small-molecule inhibitors designed to block the ATP-binding pocket of these kinases to dampen inflammatory responses [ClinicalTrials.gov]. Despite significant investment, many JNK and p38 inhibitors have faced challenges in clinical trials due to dose-limiting toxicities and lack of sustained efficacy [PubMed: 18442405]. Understanding the crosstalk between these two pathways is vital for developing more selective and effective therapeutic interventions.

Other names

Stress-activated protein kinaseSAPKMAPK8MAPK9MAPK10MAPK11MAPK12MAPK13MAPK14c-Jun N-terminal kinasep38 mitogen-activated protein kinase

Small molecule inhibition of the ATP-binding site or allosteric sites of JNK and p38 kinases, thereby preventing the phosphorylation of downstream targets and reducing the production of pro-inflammatory cytokines.